The Institute for Clinical and Economic Review (ICER) on Nov. 20 released a new report outlining a planned review of the comparative clinical effectiveness and value of peanut allergy therapies.
According to a press release, the review will assess two treatments: DBV Technologies’ Viaskin Peanut and Aimmune Therapeutics’ AR101.
The California Technology Assessment Forum, one of ICER’s independent evidence appraisal committees, is slated to discuss the report on June 11. Stakeholders can submit comments to email@example.com by 5 p.m. EST Dec. 12.
A revised scoping document, according to the release, will be posted about Dec. 20.
To read the full press release, click here.